Drug intelligence / Profile preview

DE-112 vehicle solution

Development stage: Discontinued
Lead developer: Santen Pharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

DE-112 vehicle solution is the placebo control formulation used in clinical trials for DE-112 (evodenoson), an ophthalmic solution developed by Santen Inc. for the treatment of primary open-angle glaucoma and ocular hypertension. The vehicle solution contains the same inactive ingredients as the active DE-112 formulation but lacks the active pharmaceutical ingredient, evodenoson, which is an adenosine A2A receptor agonist. It was used in Phase I/II trials to evaluate the safety and intraocular pressure-lowering efficacy of evodenoson relative to a non-active control and timolol maleate.

Beyond the preview

Go deeper on DE-112 vehicle solution.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DE-112 vehicle solution.

Explore the full profile